Full-Time

Cochlear scientist

Tissue Reprogramming

Updated on 3/22/2025

Retro Biosciences

Retro Biosciences

51-200 employees

Develops therapeutics targeting aging mechanisms

Compensation Overview

$130k - $160k/yr

Mid

San Carlos, CA, USA

This is an onsite position.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Have at least 3 years of post-baccalaureate training experience in cochlear biology, rodent models, and functional analysis.
  • Possess a strong knowledge of cochlear biology, drug delivery, hearing loss models, and related functional assays.
  • Have hands-on experience with drug delivery into the inner ear, hearing tests using ABR/DPOAE, tissue dissection and sectioning, and IF/IHC imaging.
Responsibilities
  • Utilize your expertise in cochlear biology, animal models, and functional assays to investigate the rejuvenation effects and mechanisms of epigenetic reprogramming in the inner ear.
  • Design and execute cutting-edge experiments in gene delivery, disease modeling with animals, histology, imaging, and functional assays (both in vitro and in vivo) to generate proof-of-concept data and support the preclinical-to-clinical development pipeline.
  • Analyze and interpret experimental data rigorously, identifying key insights to inform decision-making and strategy.
  • Communicate findings and recommendations clearly through written reports, presentations, and regular updates to both internal and external collaborators, including both technical and non-technical audiences.
  • Lead staged gene therapy projects, working closely with fast-paced internal teams, external collaborators, and CROs to ensure that timelines, milestones, and quality standards are met.
Desired Qualifications
  • Have working experience of inner ear drug injection.
  • Have experience setting up hearing test equipment and assays, including ABR and DPOAE.
  • Have cellular reprogramming experiences.

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Its product development is organized into three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of progress. Retro Biosciences utilizes advanced technologies like single-cell multi-omics and computational biology to enhance its research and development efforts. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases rather than just treating them, positioning itself uniquely in the biotech industry. The company's goal is to reduce healthcare expenses related to aging and improve the quality of life for individuals as they age.

Company Size

51-200

Company Stage

Early VC

Total Funding

$180M

Headquarters

Redwood City, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Retro Biosciences secured $1 billion in funding to extend human lifespan.
  • Partnership with Multiply Labs enhances cell therapy manufacturing efficiency.
  • Collaboration with OpenAI improves stem cell production through AI models.

What critics are saying

  • Ethical concerns over longevity research may lead to regulatory scrutiny.
  • AI development may outpace regulatory frameworks, posing compliance challenges.
  • Technical challenges in automated cell therapy manufacturing could delay timelines.

What makes Retro Biosciences unique

  • Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
  • The company aims to extend healthy human lifespan by ten years.
  • Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Parental Leave

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

6%
Fortune
Jan 24th, 2025
Retro Biosciences Secures $1B for Longevity

Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.

HK Silicon
Jan 23rd, 2025
Retro Biosciences to Raise $1B Funding

Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.

TechStory
Jan 18th, 2025
Experts Believe OpenAI's New AI Model Might Help in Extending Human Life

OpenAI has developed a specialized AI model, GPT-4b Micro, in collaboration with Retro Biosciences, a startup focused on extending human lifespan by ten years.

BD Pratidin
Jan 18th, 2025
OpenAI, Retro Biosciences working to extend 'human lifespan'

OpenAI, in partnership with longevity startup Retro Biosciences, has reportedly developed an artificial intelligence model aimed at enhancing the efficiency of stem cell production.

Longevity Technology
May 15th, 2024
Multiply Labs inks $85m deal with Retro Bio to automate cell therapy manufacturing

Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.